Medexus Pharmaceuticals Inc. (TSE:MDP) Receives C$5.49 Consensus Target Price from Analysts

Shares of Medexus Pharmaceuticals Inc. (TSE:MDP) have been given an average rating of “Buy” by the seven research firms that are currently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating, one has issued a buy rating and four have given a strong buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is C$5.49.

MDP has been the topic of several recent research reports. Alliance Global Partners upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a report on Monday, December 23rd. Stifel Nicolaus downgraded Medexus Pharmaceuticals from a “buy” rating to a “hold” rating and cut their price target for the stock from C$6.00 to C$3.45 in a report on Friday, February 7th. Raymond James upgraded Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price target on the stock in a report on Wednesday, January 8th. Ventum Financial increased their price objective on Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the company a “buy” rating in a report on Thursday, January 30th. Finally, Stifel Canada downgraded Medexus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th.

Medexus Pharmaceuticals Price Performance

Shares of TSE MDP opened at C$2.54 on Wednesday. The stock’s 50-day moving average is C$3.44 and its two-hundred day moving average is C$2.92. Medexus Pharmaceuticals has a 1-year low of C$1.47 and a 1-year high of C$5.56. The company has a market cap of C$56.87 million, a price-to-earnings ratio of 12.15 and a beta of 1.96.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.